{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:28Z","timestamp":1787725828624,"version":"build-2784847793"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"DAMD","award":["W81XWH-10-1-0390"],"award-info":[{"award-number":["W81XWH-10-1-0390"]}]},{"DOI":"10.13039\/100008540","name":"Diana Helis Henry Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12DK0083014"],"award-info":[{"award-number":["K12DK0083014"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008540","name":"Diana Helis Henry Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s12672-016-0257-2","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T15:45:10Z","timestamp":1457451910000},"page":"196-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy"],"prefix":"10.1007","volume":"7","author":[{"given":"Huiying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay N.","family":"Mediwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Szafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"issue":"6","key":"257_CR1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","volume":"12","author":"KJ Pienta","year":"2006","unstructured":"Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6):1665\u20131671","journal-title":"Clin Cancer Res"},{"issue":"4","key":"257_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ncponc0765","volume":"4","author":"ME Taplin","year":"2007","unstructured":"Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4(4):236\u2013244","journal-title":"Nat Clin Pract Oncol"},{"issue":"10","key":"257_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","volume":"10","author":"Y Chen","year":"2009","unstructured":"Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10(10):981\u2013991","journal-title":"Lancet Oncol"},{"issue":"7","key":"257_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-10-0567","volume":"17","author":"G Attard","year":"2011","unstructured":"Attard G, Richards J, de Bono JS (2011) New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17(7):1649\u20131657","journal-title":"Clin Cancer Res"},{"issue":"13","key":"257_CR5","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"GA Potter","year":"1995","unstructured":"Potter GA, Barrie SE, Jarman M, Rowlands MG (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 38(13):2463\u20132471","journal-title":"J Med Chem"},{"issue":"7","key":"257_CR6","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1021\/jm901488g","volume":"53","author":"ME Jung","year":"2010","unstructured":"Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53(7):2779\u20132796","journal-title":"J Med Chem"},{"issue":"21","key":"257_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"2","key":"257_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"13","key":"257_CR9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"11","key":"257_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028\u20131038","journal-title":"N Engl J Med"},{"key":"257_CR11","doi-asserted-by":"crossref","unstructured":"Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ (2015) Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget","DOI":"10.18632\/oncotarget.3925"},{"issue":"13","key":"257_CR12","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13):5469\u20135477","journal-title":"Cancer Res"},{"issue":"1","key":"257_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16\u201322","journal-title":"Cancer Res"},{"issue":"6","key":"257_CR14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305\u20132313","journal-title":"Cancer Res"},{"key":"257_CR15","doi-asserted-by":"publisher","first-page":"16759","DOI":"10.1073\/pnas.1012443107","volume":"107","author":"PA Watson","year":"2010","unstructured":"Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Inaugural Article: constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107:16759\u201316765","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"257_CR16","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1172\/JCI41824","volume":"120","author":"S Sun","year":"2010","unstructured":"Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8):2715\u20132730","journal-title":"J Clin Invest"},{"key":"257_CR17","doi-asserted-by":"crossref","unstructured":"Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res","DOI":"10.1158\/1078-0432.CCR-13-1863"},{"issue":"1","key":"257_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/adt.2013.532","volume":"12","author":"AT Szafran","year":"2014","unstructured":"Szafran AT, Mancini MA (2014) The myImageAnalysis project: a web-based application for high-content screening. Assay Drug Dev Technol 12(1):87\u201399","journal-title":"Assay Drug Dev Technol"},{"issue":"9","key":"257_CR19","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","volume":"70","author":"CJ Lai","year":"2010","unstructured":"Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J et al (2010) CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 70(9):3647\u20133656","journal-title":"Cancer Res"},{"key":"257_CR20","first-page":"115","volume":"37","author":"JS Horoszewicz","year":"1980","unstructured":"Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK et al (1980) The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115\u2013132","journal-title":"Prog Clin Biol Res"},{"key":"257_CR21","first-page":"16","volume":"17","author":"ME Kaighn","year":"1979","unstructured":"Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol 17:16\u201323","journal-title":"Investig Urol"},{"issue":"2","key":"257_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3181\/00379727-87-21419","volume":"87","author":"WF Scherer","year":"1954","unstructured":"Scherer WF, Hoogasian AF (1954) Preservation at subzero temperatures of mouse fibroblasts (strain L) and human epithelial cells (strain HeLa). Proc Soc Exp Biol Med 87(2):480\u2013487","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"257_CR23","first-page":"163","volume":"15","author":"S Korenchuk","year":"2001","unstructured":"Korenchuk S, Lehr JE, Mclean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ (2001) VCaP, a cell-based model system of human prostate cancer. Vivo 15(2):163\u2013168","journal-title":"Vivo"},{"issue":"7","key":"257_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","volume":"35","author":"RM Sramkoski","year":"1999","unstructured":"Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35(7):403\u2013409","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"10","key":"257_CR25","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer [published erratum appears in Cancer Res 1994 Jul 15;54(14):3953]. Cancer Res 54(10):2577\u20132581","journal-title":"Cancer Res"},{"issue":"45","key":"257_CR26","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1038\/onc.2011.637","volume":"31","author":"Y Li","year":"2012","unstructured":"Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31(45):4759\u20134767","journal-title":"Oncogene"},{"issue":"6","key":"257_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.steroids.2012.12.013","volume":"78","author":"AA Shafi","year":"2013","unstructured":"Shafi AA, Cox MB, Weigel NL (2013) Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78(6):548\u2013554","journal-title":"Steroids"},{"key":"257_CR28","doi-asserted-by":"crossref","unstructured":"Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49\u201359","DOI":"10.1016\/j.biocel.2014.06.013"},{"issue":"3","key":"257_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/pros.22566","volume":"73","author":"SN Mediwala","year":"2013","unstructured":"Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, Thiagarajan P, Mancini MA, Marcelli M (2013) The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate 73(3):267\u2013277","journal-title":"Prostate"},{"issue":"11","key":"257_CR30","doi-asserted-by":"publisher","first-page":"e3605","DOI":"10.1371\/journal.pone.0003605","volume":"3","author":"AT Szafran","year":"2008","unstructured":"Szafran AT, Szwarc M, Marcelli M, Mancini MA (2008) Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS ONE 3(11):e3605","journal-title":"PLoS ONE"},{"issue":"4","key":"257_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pros.10261","volume":"56","author":"S Murthy","year":"2003","unstructured":"Murthy S, Marcelli M, Weigel NL (2003) Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate 56(4):293\u2013304","journal-title":"Prostate"},{"key":"257_CR32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","volume":"173","author":"J Veldscholdte","year":"1990","unstructured":"Veldscholdte J, Ris-Stalpers C, Kuiper GGJM, Jentser G, Berrevoets C, Claassen E, Rooij HCJV, Trapman J, Brinkmann AO, Mulder E (1990) A mutation in the ligand binding domain of the androgen receptor of LnCAP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534\u2013540","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"257_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/mend.11.4.9906","volume":"11","author":"J Tan","year":"1997","unstructured":"Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere WRW, Pretlow TG, Harris SE et al (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11(4):450\u2013459","journal-title":"Mol Endocrinol"},{"issue":"3","key":"257_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/pros.10290","volume":"57","author":"A van Bokhoven","year":"2003","unstructured":"van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57(3):205\u2013225","journal-title":"Prostate"},{"issue":"1","key":"257_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/pros.1048","volume":"47","author":"A Chlenski","year":"2001","unstructured":"Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R (2001) Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47(1):66\u201375","journal-title":"Prostate"},{"issue":"23","key":"257_CR36","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","volume":"287","author":"SC Chan","year":"2012","unstructured":"Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287(23):19736\u201319749","journal-title":"J Biol Chem"},{"issue":"3","key":"257_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","volume":"9","author":"V Novotny-Diermayr","year":"2010","unstructured":"Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9(3):642\u2013652","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"257_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M Fournel","year":"2008","unstructured":"Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7(4):759\u2013768","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"257_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/embor.2009.88","volume":"10","author":"A Nebbioso","year":"2009","unstructured":"Nebbioso A, Manzo F, Miceli M, Conte M, Manente L, Baldi A, De Luca A, Rotili D, Valente S, Mai A et al (2009) Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 10(7):776\u2013782","journal-title":"EMBO Rep"},{"issue":"5","key":"257_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2008.9","volume":"22","author":"S Balasubramanian","year":"2008","unstructured":"Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22(5):1026\u20131034","journal-title":"Leukemia"},{"issue":"1","key":"257_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1677\/erc.1.01100","volume":"13","author":"A Angelucci","year":"2006","unstructured":"Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1):197\u2013210","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"257_CR42","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1158\/0008-5472.CAN-06-3559","volume":"67","author":"JP Jani","year":"2007","unstructured":"Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC et al (2007) Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res 67(20):9887\u20139893","journal-title":"Cancer Res"},{"issue":"1","key":"257_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0092-8674(78)90305-7","volume":"14","author":"EP Candido","year":"1978","unstructured":"Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14(1):105\u2013113","journal-title":"Cell"},{"issue":"12","key":"257_CR44","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1210\/mend.13.12.0382","volume":"13","author":"LV Nazareth","year":"1999","unstructured":"Nazareth LV, Stenoien DL, Bingman WE 3rd, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ et al (1999) A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 13(12):2065\u20132075","journal-title":"Mol Endocrinol"},{"issue":"6","key":"257_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0092-8674(03)00934-6","volume":"115","author":"R Metivier","year":"2003","unstructured":"Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F (2003) Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115(6):751\u2013763","journal-title":"Cell"},{"issue":"12","key":"257_CR46","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1210\/endo.141.12.7837","volume":"141","author":"JF Zhang","year":"2000","unstructured":"Zhang JF, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141(12):4698\u20134710","journal-title":"Endocrinology"},{"issue":"12","key":"257_CR47","first-page":"3698","volume":"35","author":"P Janik","year":"1975","unstructured":"Janik P, Briand P, Hartmann NR (1975) The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35(12):3698\u20133704","journal-title":"Cancer Res"},{"key":"257_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/0960-0760(92)90401-4","volume":"41","author":"J Veldscholte","year":"1992","unstructured":"Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665\u2013669","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"29","key":"257_CR49","doi-asserted-by":"publisher","first-page":"25904","DOI":"10.1074\/jbc.M203423200","volume":"277","author":"L Gaughan","year":"2002","unstructured":"Gaughan L, Logan IR, Cook S, Neal DE, Robson CN (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277(29):25904\u201325913","journal-title":"J Biol Chem"},{"issue":"3","key":"257_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1097-2765(02)00471-9","volume":"9","author":"Y Shang","year":"2002","unstructured":"Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9(3):601\u2013610","journal-title":"Mol Cell"},{"issue":"11","key":"257_CR51","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","volume":"21","author":"G Lagger","year":"2002","unstructured":"Lagger G, O\u2019Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T et al (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21(11):2672\u20132681","journal-title":"EMBO J"},{"issue":"5","key":"257_CR52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","volume":"18","author":"JJ Kovacs","year":"2005","unstructured":"Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18(5):601\u2013607","journal-title":"Mol Cell"},{"issue":"18","key":"257_CR53","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18):5913\u20135925","journal-title":"Clin Cancer Res"},{"issue":"4","key":"257_CR54","doi-asserted-by":"publisher","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E Hornberg","year":"2011","unstructured":"Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4):e19059","journal-title":"PLoS One"},{"issue":"9","key":"257_CR55","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B et al (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3(9):1020\u20131029","journal-title":"Cancer Discov"},{"issue":"5","key":"257_CR56","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","volume":"154","author":"KH Chang","year":"2013","unstructured":"Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X et al (2013) A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154(5):1074\u20131084","journal-title":"Cell"},{"issue":"6","key":"257_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C et al (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309\u20131322","journal-title":"Cell"},{"issue":"7","key":"257_CR58","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1172\/JCI66398","volume":"123","author":"JK Myung","year":"2013","unstructured":"Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K et al (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123(7):2948\u20132960","journal-title":"J Clin Invest"},{"issue":"6","key":"257_CR59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","volume":"17","author":"RJ Andersen","year":"2010","unstructured":"Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6):535\u2013546","journal-title":"Cancer Cell"},{"issue":"6","key":"257_CR60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1535-7163.MCT-12-1045","volume":"12","author":"J Wang","year":"2013","unstructured":"Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P et al (2013) Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 12(6):925\u2013936","journal-title":"Mol Cancer Ther"},{"key":"257_CR61","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA et al (2015) Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget","DOI":"10.18632\/oncotarget.3268"},{"issue":"19","key":"257_CR62","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-14-0570","volume":"20","author":"T Shimizu","year":"2014","unstructured":"Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A et al (2014) Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res 20(19):5032\u20135040","journal-title":"Clin Cancer Res"},{"issue":"7","key":"257_CR63","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","volume":"21","author":"TJ Galloway","year":"2015","unstructured":"Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R et al (2015) A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21(7):1566\u20131573","journal-title":"Clin Cancer Res"},{"issue":"6","key":"257_CR64","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/0092-8674(91)90554-C","volume":"65","author":"LK Durrin","year":"1991","unstructured":"Durrin LK, Mann RK, Kayne PS, Grunstein M (1991) Yeast histone H4 N-terminal sequence is required for promoter activation in vivo. Cell 65(6):1023\u20131031","journal-title":"Cell"},{"issue":"12","key":"257_CR65","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1210\/me.2009-0188","volume":"23","author":"J Ai","year":"2009","unstructured":"Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z (2009) HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 23(12):1963\u20131972","journal-title":"Mol Endocrinol"},{"issue":"23","key":"257_CR66","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1128\/MCB.23.23.8563-8575.2003","volume":"23","author":"M Fu","year":"2003","unstructured":"Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C et al (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23(23):8563\u20138575","journal-title":"Mol Cell Biol"},{"issue":"27","key":"257_CR67","doi-asserted-by":"publisher","first-page":"20853","DOI":"10.1074\/jbc.M000660200","volume":"275","author":"M Fu","year":"2000","unstructured":"Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG (2000) p300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275(27):20853\u201320860","journal-title":"J Biol Chem"},{"issue":"3","key":"257_CR68","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","volume":"69","author":"DS Welsbie","year":"2009","unstructured":"Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69(3):958\u2013966","journal-title":"Cancer Res"},{"issue":"11","key":"257_CR69","doi-asserted-by":"publisher","first-page":"e27178","DOI":"10.1371\/journal.pone.0027178","volume":"6","author":"L Ellis","year":"2011","unstructured":"Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R (2011) Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PLoS One 6(11):e27178","journal-title":"PLoS One"},{"issue":"11","key":"257_CR70","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1021\/cb400542w","volume":"8","author":"BE Gryder","year":"2013","unstructured":"Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, Khan S, Oyelere AK (2013) Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem Biol 8(11):2550\u20132560","journal-title":"ACS Chem Biol"},{"issue":"3","key":"257_CR71","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1530\/ERC-12-0240","volume":"20","author":"GL Gravina","year":"2013","unstructured":"Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V et al (2013) PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer 20(3):321\u2013337","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"257_CR72","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/onc.2010.600","volume":"30","author":"Y Yang","year":"2011","unstructured":"Yang Y, Tse AK, Li P, Ma Q, Xiang S, Nicosia SV, Seto E, Zhang X, Bai W (2011) Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 30(19):2207\u20132218","journal-title":"Oncogene"},{"issue":"1","key":"257_CR73","doi-asserted-by":"publisher","first-page":"e54102","DOI":"10.1371\/journal.pone.0054102","volume":"8","author":"L Bellucci","year":"2013","unstructured":"Bellucci L, Dalvai M, Kocanova S, Moutahir F, Bystricky K (2013) Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS One 8(1):e54102","journal-title":"PLoS One"},{"issue":"2","key":"257_CR74","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1006\/bbrc.1997.7158","volume":"237","author":"H Xiao","year":"1997","unstructured":"Xiao H, Hasegawa T, Miyaishi O, Ohkusu K, Isobe K (1997) Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF\/CIP1 in p53-independent manner. Biochem Biophys Res Commun 237(2):457\u2013460","journal-title":"Biochem Biophys Res Commun"},{"issue":"49","key":"257_CR75","doi-asserted-by":"publisher","first-page":"34940","DOI":"10.1074\/jbc.274.49.34940","volume":"274","author":"LC Sambucetti","year":"1999","unstructured":"Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274(49):34940\u201334947","journal-title":"J Biol Chem"},{"issue":"5","key":"257_CR76","first-page":"1129","volume":"22","author":"WH Park","year":"2003","unstructured":"Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, Lee MH, Kang WK, Park K (2003) Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis. Int J Oncol 22(5):1129\u20131134","journal-title":"Int J Oncol"},{"issue":"49","key":"257_CR77","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):5501\u20135511","journal-title":"Oncogene"},{"issue":"14","key":"257_CR78","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-12-3385","volume":"73","author":"H Reuveni","year":"2013","unstructured":"Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A (2013) Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73(14):4383\u20134394","journal-title":"Cancer Res"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-016-0257-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0257-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:50:48Z","timestamp":1609264248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-016-0257-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1007\/s12672-016-0257-2","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]},"assertion":[{"value":"27 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}